{"id":9883,"date":"2024-01-15T21:02:00","date_gmt":"2024-01-15T13:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=9883"},"modified":"2024-10-27T21:11:10","modified_gmt":"2024-10-27T13:11:10","slug":"pfizer-eyes-further-adc-expansion-potentially-in-china-says-chief-oncology-officer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=9883","title":{"rendered":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer"},"content":{"rendered":"\n<p>Dr. Chris Boshoff, Pfizer (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>)&#8217;s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese firms. According to Boshoff, Pfizer&#8217;s significant appetite for ADCs remains unsatisfied following the $43 billion acquisition of Seagen, which concluded in December 2023. He noted that the company is &#8220;looking at opportunities from companies in the Far East now, and certainly also companies in China, which is important in this whole area, especially ADC development.&#8221;<\/p>\n\n\n\n<p>Boshoff indicated that any prospective deal would likely be of a more modest scale given Pfizer&#8217;s recent substantial expenditure, suggesting that a licensing agreement could also be on the table. Pfizer and Seagen have already inked one ADC-focused deal with Chinese partners. In December 2023, just before the closure of Pfizer&#8217;s acquisition of Seagen, Seagen entered into an agreement with Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>), and Medilink Therapeutics. This global clinical development and commercialization rights deal for the mesothelin-targeted ADC HBM9033, co-developed by Nona and Medilink, included an upfront payment of $53 million and potential milestone payments of up to $1.05 billion.<\/p>\n\n\n\n<p>Dr. Boshoff&#8217;s promotion to chief oncology officer from his previous role leading clinical research of oncology and rare disease products occurred in July 2023. He now reports directly to CEO Albert Bourla as part of a corporate restructuring in response to the Seagen acquisition. This restructuring has resulted in a unified oncology entity that integrates Seagen&#8217;s existing team and maintains a focus on the entire process from discovery to commercialization.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Chris Boshoff, Pfizer (NYSE: PFE)&#8217;s recently appointed chief oncology officer, disclosed in an interview&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[129,916,372,863,309],"class_list":["post-9883","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hbm-holdings","tag-hkg-2142","tag-medilink-therapeutics","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dr. Chris Boshoff, Pfizer (NYSE: PFE)&#039;s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese firms. According to Boshoff, Pfizer&#039;s significant appetite for ADCs remains unsatisfied following the $43 billion acquisition of Seagen, which concluded in December 2023. He noted that the company is &quot;looking at opportunities from companies in the Far East now, and certainly also companies in China, which is important in this whole area, especially ADC development.&quot;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=9883\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=9883\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-15T13:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-27T13:11:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer\",\"datePublished\":\"2024-01-15T13:02:00+00:00\",\"dateModified\":\"2024-10-27T13:11:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883\"},\"wordCount\":298,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HBM Holdings\",\"HKG: 2142\",\"MediLink Therapeutics\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9883#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=9883\",\"name\":\"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-01-15T13:02:00+00:00\",\"dateModified\":\"2024-10-27T13:11:10+00:00\",\"description\":\"Dr. Chris Boshoff, Pfizer (NYSE: PFE)'s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese firms. According to Boshoff, Pfizer's significant appetite for ADCs remains unsatisfied following the $43 billion acquisition of Seagen, which concluded in December 2023. He noted that the company is \\\"looking at opportunities from companies in the Far East now, and certainly also companies in China, which is important in this whole area, especially ADC development.\\\"\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9883\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9883#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer - Insight, China&#039;s Pharmaceutical Industry","description":"Dr. Chris Boshoff, Pfizer (NYSE: PFE)'s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese firms. According to Boshoff, Pfizer's significant appetite for ADCs remains unsatisfied following the $43 billion acquisition of Seagen, which concluded in December 2023. He noted that the company is \"looking at opportunities from companies in the Far East now, and certainly also companies in China, which is important in this whole area, especially ADC development.\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=9883","og_locale":"en_US","og_type":"article","og_title":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=9883","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-01-15T13:02:00+00:00","article_modified_time":"2024-10-27T13:11:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=9883#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=9883"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer","datePublished":"2024-01-15T13:02:00+00:00","dateModified":"2024-10-27T13:11:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=9883"},"wordCount":298,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HBM Holdings","HKG: 2142","MediLink Therapeutics","NYSE: PFE","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=9883#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=9883","url":"https:\/\/flcube.com\/?p=9883","name":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-01-15T13:02:00+00:00","dateModified":"2024-10-27T13:11:10+00:00","description":"Dr. Chris Boshoff, Pfizer (NYSE: PFE)'s recently appointed chief oncology officer, disclosed in an interview with FiercePharma.com on the margins of the JP Morgan Healthcare Conference that the company is contemplating additional strategic deals, particularly in the realm of antibody drug conjugates (ADCs), with a focus that may include Chinese firms. According to Boshoff, Pfizer's significant appetite for ADCs remains unsatisfied following the $43 billion acquisition of Seagen, which concluded in December 2023. He noted that the company is \"looking at opportunities from companies in the Far East now, and certainly also companies in China, which is important in this whole area, especially ADC development.\"","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=9883#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=9883"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=9883#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9883"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9883\/revisions"}],"predecessor-version":[{"id":9884,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9883\/revisions\/9884"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}